Tourmaline Bio Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Year Ending	TTM	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019
Net Income	-32.94	-42.12	-19.7	-47.83	-22.71	-18.16
Depreciation & Amortization	-0.44	0.16	0.02	0.62	0.45	0.38
Share-Based Compensation	3.5	5.77	0.2	3.78	1.02	0.23
Other Operating Activities	3.77	8.12	13.03	3.44	2.03	-0.11
Operating Cash Flow	-26.1	-28.08	-6.46	-39.99	-19.21	-17.66
Capital Expenditures	0.26	-0.06	-0.07	-2.44	-1.29	-0.56
Change in Investments	-212.7	3.9	0	-93.95	-132.01	0
Other Investing Activities	-	-	-5	-	-0	-
Investing Cash Flow	-212.44	3.84	-5.07	-96.39	-133.3	-0.56
Share Issuance / Repurchase	231.92	70.61	0	137.68	1.65	0
Debt Issued / Paid	0	0	-0.15	0	0	0
Other Financing Activities	86.11	86.11	20	-0.28	129.47	36.2
Financing Cash Flow	318.03	156.72	19.85	137.4	131.12	36.2
Net Cash Flow	79.49	132.48	8.32	1.03	-21.39	17.98
Free Cash Flow	-25.84	-28.14	-6.53	-42.43	-20.5	-18.22
Free Cash Flow Per Share	-1.07	-5.93	-7.44	-14.57	-30.66	-28.55

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).